ProThera Biologics is a biotherapeutics company developing Inter-Alpha Inhibitor Proteins (IAIP) to treat severe inflammation associated with infection, trauma and disease.

Inter-Alpha Inhibitor Proteins are:

  • Naturally occurring human plasma proteins
  • A first line of host defense against severe inflammation
  • Essential to human health
  • We are developing IAIP therapy to:

  • Suppress severe inflammatory disease
  • Complement conventional treatments
  • Promote rapid and complete recovery of patients
  • IAIP are proteins found in the blood of all mammals and play a critical and essential role in managing and preventing the adverse effects of inflammation. IAIP are essential to health and act as endogenous defenders against severe inflammation.

    ProThera has demonstrated the promise of IAIP for the treatment of inflammatory disease in many animal models and has shown that IAIP blood levels correlate closely with the degree of severity of inflammatory disease in humans.

    We expect to introduce IAIP as a replacement therapy in critical disease states where IAIP levels decrease as a result of the underlying disease process. IAIP replacement therapy will function as an adjunct to current therapy to:

  • improve recovery
  • reduce mortality and
  • reduce costs of medical care
  • Applications for IAIP include a host of severe, acute inflammatory diseases including those resulting from infection, injury or trauma. ProThera is targeting high unmet medical needs where there are no treatments for the inflammatory process.


  • ProThera Biologics Awarded $1.95-Million NIH Grant - ProThera Biologics and Women & Infants Hospital to Use Funding to Study Treatment for Infant Brain Injury
  • ProThera Biologics today announced that it has been awarded a $1.95-million Phase II Small Business Innovation Research (SBIR) grant by the National Institutes of Health (NIH) to study the potential of Inter-Alpha Inhibitor Proteins (IAIP) to prevent and treat neonatal hypoxic ischemic brain injury.

    ProThera collaborated with Women & Infants Hospital (WIH) on the pilot phase of the study, which was supported by a 2010 research grant from the Rhode Island Science and Technology Advisory Council (STAC). Based on the success achieved during Phase I, ProThera was issued the second round of SBIR grant funding. ProThera will work once again with Dr. Barbara Stonestreet, M.D., a neonatal- perinatal specialist at WIH and professor of pediatrics at the Warren Alpert School of Medicine at Brown University, and Xiaodi Chen, M.D., Ph.D., a key member of her team, to conduct the Phase II study.

    Since inception, ProThera has invested an aggregate of $12 million in the preclinical development of IAIP, funded primarily from peer-reviewed grants awarded by the NIH....[Press Release]

  • November 21, 2016

    ProThera Biologics, Inc. has been awarded a $50,000 Innovation Voucher from the Rhode Island Commerce Corporation to support a study in collaboration with Rhode Island Hospital (RIH). ProThera Biologics is a biotherapeutics company developing Inter-alpha Inhibitor Proteins (IAIP) therapy to treat patients with life threatening diseases. IAIP are natural, circulating proteins which are essential for human health; the levels of these proteins are normally high in healthy individuals but drop rapidly in patients who are fighting severe inflammation. In this project, ICU patients at Rhode Island Hospital diagnosed with severe pneumonia will be enrolled to study the blood levels of IAIP to support ProThera’s planned clinical trials of this novel treatment. Dr. Mitchel Levy, Medical Director of the Intensive Care Unit, Division of Critical Care, Pulmonary and Sleep Medicine, will be the principal investigator at Rhode Island Hospital.

  • Women’s and Infant’s Hospital receives 2 NIH grants and will work with ProThera to study IAIP in infant brain injury
  • Slater Reinvests in ProThera Biologics
  • ProThera Biologics Appoints New COO
  • ProThera Biologics Appoints New President & CBO